Premium
The correlation between the loss of chromosome 14q with histologic tumor grade, pathologic stage, and outcome of patients with nonpapillary renal cell carcinoma
Author(s) -
Wu ShiQi,
Hafez G. Reza,
Xing Weirong,
Newton Michael,
Chen XiaoRong,
Messing Edward
Publication year - 1996
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/(sici)1097-0142(19960315)77:6<1154::aid-cncr23>3.0.co;2-#
Subject(s) - renal cell carcinoma , stage (stratigraphy) , fluorescence in situ hybridization , medicine , pathology , chromosome , carcinoma , cancer , oncology , biology , genetics , gene , paleontology
BACKGROUND Conventional pathologic classifications of human renal cell carcinoma (RCC) give little insight into oncogenesis and little assistance in predicting the clinical behavior of this disease. Identification of specific genetic alterations involved in the development of RCC using fluorescence in situ hybridization (FISH) however, may help provide foundations for classification, prognosis, and clinical management of the patients. METHODS Archival, paraffin embedded tissue sections from 30 human non‐papillary RCCs were examined with a dual color FISH technique for loss of chromosomes 3p and 14q. Telomeric DNA probes from 3p or 14q and an internal ploidy control probe, centromeric probe of chromosome 2, were applied directly to the tumor sections. The correlations between loss of 3p or 14q, and tumor ploidy, with tumor grade, pathologic stage, and patient outcome were assessed. RESULTS Ninety percent of the patients (27) lost chromosome 3p, and 36.7% of the patients (11) had chromosome 14q deletions. The loss of 3p in the samples tested was unrelated to patient age, gender, outcome, tumor stage, or histologic grade. However, the deletion of 14q was significantly correlated with higher stage ( P = 0.01), histologic grade ( P = 0.01), and patient outcome ( P < 10 −4 ). CONCLUSION The close correlation of 14q loss with higher stage, higher histologic grade, and poorer outcome for patients with nonpapillary RCC indicates that it may be a promising prognostic marker. Cancer 1996;77:1154‐60.